Spondyloarthritis & psoriatic arthritis
No difference in clinical parameters and drug retention in psoriatic arthritis (PsA) patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry
Authors' conclusion
We did not identify any clinical parameters with notable influence on the choice of b/tsDMARD mono or MTX-combination therapy in PsA. Drug retention rates are similar between mono and combination therapy.
Study context
- Population
- PsA patients starting b/tsDMARD in the RABBIT-SpA registry
- Participants
- 900 vs 405
- Exposure
- b/tsDMARD monotherapy vs b/tsDMARD in combination with methotrexate (MTX)
- Monotherapyn = 900reference
- Combinationn = 405
- Outcome
- Drug retention (drug survival analysis)
Methodological detailsregistry (RABBIT-SpA), drug survival analysis
- Registry (RABBIT-SpA)
- Drug survival analysis
Main finding
As reported in the abstract
Drug retention
Still on original treatment at 6 months
Still on original treatment at 12 months
- Combination vs Monotherapy: P = 0.4 — drug retention rates did not differ
Observational data: associations, not effects.
Further findings
Baseline clinical domains (skin, nail, joint, dactylitis, enthesitis, axial involvement)
- Similar between the groups
Patients' satisfaction with tolerability of previous treatment · treatment start
- Significantly better in the combination group
Original publication
No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry. RMD Open. Published 23 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →